Tocilizumab resolves refractory macular edema associated to retinitis pigmentosa.

Silvia Mendez-MartínezNieves Pardiñas BarónFrancisco de Asís Bartol-PuyalBorja Arias Del PesoMaría Pilar Ruiz Del TiempoÁlvaro Lesta ArnalOscar Ruiz MorenoJavier Manero RuizLuis Pablo Júlvez

Published in: Retinal cases & brief reports (2022)

CME causes visual impairment in RP, but current treatments are usually deficient. Tocilizumab has been successfully used as treatment for refractory CME in uveitis, retinal dystrophies, and autoimmune retinopathies. This article reports, for the first time, the long-term resolution of refractory CME in RP with intravenous tocilizumab.

Keyphrases

juvenile idiopathic arthritis
rheumatoid arthritis
optical coherence tomography
rheumatoid arthritis patients
diabetic retinopathy
disease activity
ankylosing spondylitis
multiple sclerosis
high dose
emergency department
systemic lupus erythematosus
single molecule
low dose
replacement therapy